This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products/services being delivered include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect live Mycobacterium tuberculosis (MTB) and...
This $287,878,180 Cooperative Agreement award by the U.S. Agency for International Development (USAID) under the Foreign Assistance for Programs Overseas (CFDA 98.001) program is intended to scale up and improve the management of drug-resistant tuberculosis (DR-TB) in USAID-supported countries. It will focus on expanding access to high-quality DR-TB treatment services and providing specialized technical assistance to enhance the quality of DR-TB programs at the country level. The prime...
This federal Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Health Department Based program (CFDA 93.940) provides $785,722 to the Indiana Department of Health (IDOH) to support comprehensive tuberculosis (TB) prevention, control, and laboratory strengthening activities in Indiana. The award aims to assist IDOH in addressing the increasing TB incidence in the state, which rose 31% from 2022 to 2023, and progress toward...
The federal Cooperative Agreement award, funded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program, provides $6,480,574 to the Tropical Disease Foundation Inc. (TDF) to implement the "TUBERCULOSIS-FREE VISAYAS AND MINDANAO" project in the Philippines. The project aims to control and prevent the spread of tuberculosis in the Visayas and Mindanao regions of the Philippines over a 5-year period from...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $743,698 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University to characterize the burden, severity, and phenotypic presentation of post-tuberculosis lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in tuberculosis (TB) patients with and without HIV. The project will leverage an ongoing TB research consortium in India to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405 to Colorado State University to develop new 3-4 drug regimens containing the spectinamide antibiotic administered via inhalation for the treatment of drug-sensitive and multidrug-resistant tuberculosis (TB). The key objectives are to: 1) manufacture and characterize larger quantities of the spectinamide dry...
The Defense Health Agency awarded a $215,429 Project Grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis. This two-year grant, running from July 2024 to July 2026, supports TB Alliance's research and development efforts to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The funding falls under the Military...
This federal Project Grant award, with ID R56AI180517, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $749,414 grant, awarded on August 1, 2024, supports research to understand the role of the macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and explore whether targeting MDR1 can shorten tuberculosis (TB) treatment duration. The key research aims...
This $7,000,000 Cooperative Agreement award from the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program supports actions to fight tuberculosis (TB) in the Philippines over a 5-year period from October 2024 to September 2029. The project, titled "ACTIONS TO SUPPORT WIDE-SCALE INTERVENTIONS TO FIGHT TB IN THE PHILIPPINES (ACT SWIFT)", will be implemented by the Philippine Tuberculosis Society, Inc. This award...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing pro-apoptotic drugs as host-directed treatments for pulmonary tuberculosis (TB). The $774,881 award will support research to understand how pro-apoptotic drugs, such as navitoclax, can be used to shorten TB treatments and prevent post-TB lung disease. The researchers will leverage advanced...